{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-006784","form_type":"8-K","ticker":"ACON","cik":"0001635077","company_name":"Aclarion, Inc.","filed_at":"2023-09-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.634691+00:00","generated_at":"2026-06-10T07:39:03.686531+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"medium","headline":"Aclarion updates investor deck; highlights CLARITY trial start Q4 2023 with 300 patients","bullets":["CLARITY prospective randomized trial begins Q4 2023; 300 patients, 42-month timeline, Johns Hopkins anchor site.","NIH BACPAC studies (comeBACK, BEST) using Nociscan; enrollment ongoing, expected completion Q2 2024.","CPT Category III codes 0609T and 0611T secured Jan 2021; early commercialization in progress.","39 issued US/international patents plus 13 pending; market opportunity up to $135B low back pain market."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-006784","json":"https://secwatch.observer/filing/0001683168-23-006784.json","markdown":"https://secwatch.observer/filing/0001683168-23-006784.md","text":"https://secwatch.observer/filing/0001683168-23-006784.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635077/000168316823006784/0001683168-23-006784-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635077/000168316823006784/acon_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T07:39:03.686531+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}